Artivion, Inc. (NYSE:AORT - Get Free Report)'s stock price reached a new 52-week high during trading on Thursday . The stock traded as high as $32.68 and last traded at $32.70, with a volume of 56185 shares. The stock had previously closed at $32.15.
Analyst Ratings Changes
AORT has been the topic of several research reports. JMP Securities reissued a "market outperform" rating and set a $33.00 price objective on shares of Artivion in a research note on Tuesday, May 6th. Citizens Jmp raised shares of Artivion to a "strong-buy" rating in a research note on Tuesday, May 6th. Canaccord Genuity Group assumed coverage on shares of Artivion in a research note on Tuesday, June 17th. They issued a "buy" rating and a $35.00 target price on the stock. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $32.00 target price on shares of Artivion in a research note on Tuesday, May 6th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $32.40.
Get Our Latest Research Report on AORT
Artivion Trading Down 3.3%
The firm's 50 day moving average price is $29.50 and its 200-day moving average price is $27.68. The stock has a market cap of $1.34 billion, a P/E ratio of -62.94 and a beta of 1.62. The company has a debt-to-equity ratio of 1.08, a current ratio of 5.53 and a quick ratio of 3.95.
Artivion (NYSE:AORT - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.06). Artivion had a positive return on equity of 3.63% and a negative net margin of 5.49%. The firm had revenue of $98.98 million during the quarter, compared to the consensus estimate of $94.81 million. As a group, equities research analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current year.
Insider Activity
In other news, Director Anthony B. Semedo sold 2,600 shares of the business's stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $28.47, for a total transaction of $74,022.00. Following the completion of the transaction, the director directly owned 33,059 shares of the company's stock, valued at $941,189.73. The trade was a 7.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jean F. Holloway sold 9,926 shares of the business's stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $29.00, for a total transaction of $287,854.00. Following the transaction, the senior vice president directly owned 187,258 shares of the company's stock, valued at $5,430,482. The trade was a 5.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 72,954 shares of company stock valued at $2,108,525 over the last three months. Insiders own 7.60% of the company's stock.
Institutional Trading of Artivion
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP boosted its position in shares of Artivion by 4.1% in the first quarter. Wellington Management Group LLP now owns 1,727,408 shares of the company's stock worth $42,460,000 after purchasing an additional 67,327 shares during the period. Wasatch Advisors LP raised its stake in shares of Artivion by 27.7% in the fourth quarter. Wasatch Advisors LP now owns 1,041,992 shares of the company's stock valued at $29,791,000 after acquiring an additional 226,160 shares during the period. Next Century Growth Investors LLC increased its stake in Artivion by 107.6% in the 1st quarter. Next Century Growth Investors LLC now owns 1,022,775 shares of the company's stock worth $25,140,000 after buying an additional 530,122 shares during the period. Northern Trust Corp increased its stake in Artivion by 10.0% in the 4th quarter. Northern Trust Corp now owns 463,250 shares of the company's stock worth $13,244,000 after buying an additional 42,170 shares during the period. Finally, Lord Abbett & CO. LLC increased its stake in Artivion by 31.0% in the 1st quarter. Lord Abbett & CO. LLC now owns 401,904 shares of the company's stock worth $9,879,000 after buying an additional 95,202 shares during the period. 86.37% of the stock is owned by hedge funds and other institutional investors.
About Artivion
(
Get Free Report)
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Featured Stories
Before you consider Artivion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artivion wasn't on the list.
While Artivion currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.